Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2022-03-18 | Janet S. Vergis, Director since 2014, Independent, Age: 57. Serves on Audit and Governance, Nominating and Corporate Responsibility Committees. 2021 Director Compensation Table shows total compensation of $260,000. |
| 2023-03-17 | Ms. Vergis served as an Executive Advisor for private equity firms from January 2013 to December 2019. Director since 2014, Independent, Age: 58, Compensation & Human Capital Committee, Chair Governance, Nominating & Corporate Responsibility Committee, Executive Committee. 2022 Director Compensation Table shows total $260,000. |
| 2024-03-22 | Ms. Vergis served as an Executive Advisor for private equity firms from January 2013 to December 2019. |
| 2025-03-20 | Janet S. Vergis Director since 2014 Independent Age: 60 Chair, Governance, Nominating & Corporate Responsibility Committee Compensation & Human Capital Committee Executive Committee ... 2024 DIRECTOR COMPENSATION TABLE ... Janet S. Vergis Fees Earned or Paid in Cash: 70,000 Stock Awards: 150,000 Option Awards: 80,000 Total: 300,000 |
| Filing Date | Source Excerpt |
|---|---|
| 2020-04-07 | Janet S. Vergis, Independent, Age 55, Director since 2019, Board Committees: Audit and Finance Committee, Science and Technology Committee, 2019 Director Compensation: $162,131 total. |
| 2021-04-16 | Ms. Vergis has over 30 years of experience in the healthcare industry and recently served as an executive advisor to private equity firms. Prior to her advisory role she was the Chief Executive Officer of OraPharma,lnc., a privately held, specialty pharmaceutical company focusing on oral health. In that role she led the turnaround of the business and its subsequent successful sale. Preceding her role at OraPharma, Ms. Vergis managed a multi-billion portfolio at Johnson & Johnson (NYSE: JNJ) as President of Janssen Pharmaceuticals, McNeil Pediatrics, and Ortho-McNeil Neurologics. Ms. Vergis contributed to a number of Johnson & Johnson companies during her career, serving as a member of company management boards for over 10 years and holding positions of increasing responsibility in research and development, new product development, sales, and marketing. She currently serves on the Board of Directors for Church & Dwight Co., Inc. (NYSE: CHD), Teva Pharmaceuticals (NYSE: TEVA), and SGS SA (ZUR: SGSN). |
| 2022-04-13 | Ms. Vergis has over 30 years of experience in the healthcare industry and recently served as an executive advisor to private equity firms from 2013 to 2019. Prior to her advisory role she was the Chief Executive Officer of OraPharma,lnc., a privately held, specialty pharmaceutical company focusing on oral health. In that role she led the turnaround of the business and its subsequent successful sale. Preceding her role at OraPharma, Ms. Vergis managed a $6 billion portfolio at Johnson & Johnson (NYSE: JNJ) as President of Janssen Pharmaceuticals, McNeil Pediatrics, and Ortho-McNeil Neurologies. Ms. Vergis contributed to a number of Johnson & Johnson companies during her career, serving as a member of company management boards for over 10 years and holding positions of increasing responsibility in research and development, new product development, sales, and marketing. Ms. Vergis serves on the Board of Directors for Church and Dwight Co., Inc. (NYSE: CHD), Teva Pharmaceutical Industries Ltd. and on the Board of Directors of SGS SA. And previously served on the Board of Directors of Amneal Pharmaceuticals, Inc. She is also Chair of The Biotechnology Advisory Board and a member of the Dean’s Advisory Counsel for the Eberly College of Science as well as Vice-Chair of the Corporate and Foundation Relations Advisory Board at Penn State. Ms. Vergis earned a B.S. degree in Biology and an M.S. degree in Physiology from The Pennsylvania State University. |
| 2023-04-14 | Ms. Vergis has over 35 years of experience in the healthcare industry and recently served as an executive advisor to private equity firms from 2013 to 2019. Prior to her advisory role she was the Chief Executive Officer of OraPharma,lnc., a privately held, specialty pharmaceutical company focusing on oral health. In that role, she led the turnaround of the business and its subsequent successful sale. Preceding her role at OraPharma, Ms. Vergis managed a $6 billion portfolio at Johnson & Johnson (NYSE: JNJ) as President of Janssen Pharmaceuticals, McNeil Pediatrics, and Ortho-McNeil Neurologies. Ms. Vergis contributed to a number of Johnson & Johnson companies during her career, serving as a member of company management boards for over 10 years and holding positions of increasing responsibility in research and development, new product development, sales, and marketing. Ms. Vergis serves on the Board of Directors for Church and Dwight Co., Inc. (NYSE: CHD), Teva Pharmaceutical Industries Ltd. and on the Board of Directors of SGS SA., and previously served on the Board of Directors of Amneal Pharmaceuticals, Inc. She is also Chair of The Biotechnology Advisory Board and a member of the Dean’s Advisory Counsel for the Eberly College of Science as well as Vice-Chair of the Corporate and Foundation Relations Advisory Board at Penn State. Ms. Vergis earned a B.S. degree in Biology and an M.S. degree in Physiology from The Pennsylvania State University. |
| 2024-04-10 | Janet S. Vergis Independent Age: 59 Board Committees: • Science and Technology Committee (Chair) • Human Resources Committee Other Public Company Boards: • Church & Dwight Co., Inc. • Teva Pharmaceutical Industries Ltd. Ms. Vergis has over 35 years of experience in the healthcare industry and recently served as an executive advisor to private equity firms from 2013 to 2019. Prior to her advisory role she was the Chief Executive Officer of OraPharma,lnc., a privately held, specialty pharmaceutical company focusing on oral health. In that role she led the turnaround of the business and its subsequent successful sale. Preceding her role at OraPharma, Ms. Vergis managed a multi-billion portfolio at Johnson & Johnson as President of Janssen Pharmaceuticals, McNeil Pediatrics, and Ortho-McNeil Neurologics. Ms. Vergis contributed to several Johnson & Johnson companies during her career, serving as a member of company management boards for over 10 years and holding positions of increasing responsibility in research and development, new product development, sales, and marketing. Ms. Vergis serves on the Board of Directors for Church and Dwight Co., Inc., Teva Pharmaceutical Industries Ltd., and SGS SA. She previously served on the Board of Directors of Amneal Pharmaceuticals, Inc. She is also Chair of The Biotechnology Advisory Board and Vice-Chair of the Corporate and Foundation Relations Advisory Board at Penn State. Ms. Vergis earned a B.S. degree in Biology and an M.S. degree in Physiology from The Pennsylvania State University. |
| Filing Date | Source Excerpt |
|---|---|
| 2020-04-22 | Janet S. Vergis Independent Director Nominee Ms. Vergis served from 2013 to 2019 as an executive advisor to various private equity firms, including, Warburg Pincus, Deerfield Mgmt., Water Street Healthcare Partners and Vatera Healthcare Partners. From 2011 to 2012, she served as the Chief Executive Officer of OraPharma, Inc., a specialty pharmaceutical company. From 2004 to 2009, she served as President of Janssen Pharmaceuticals LP, McNeil Pediatrics, Inc. and Ortho-McNeil Neurologics, Inc., subsidiaries of Johnson & Johnson. Ms. Vergis contributed to a number of Johnson & Johnson companies during her career, holding positions of increasing responsibility in research and development, new product development, sales and marketing. Ms. Vergis has served on the Board of Directors of Church and Dwight Co., Inc. since 2014, MedDay Pharmaceuticals since 2016 and Dentsply-Sirona, Inc. since 2019. She previously served on the board of Amneal Pharmaceutical until 2019, as well as Lumara Health and OraPharma, Inc. Ms. Vergis received a Bachelor of Science in Biology and a Masters of Science in Physiology from The Pennsylvania State University. With over 30 years of experience in many aspects of the healthcare industry, including research and development, new product development, sales, and various executive roles, as well as her experience as a board member of public pharmaceutical companies, Ms. Vergis will provide the Board with broad global business experience in the pharmaceutical industry. |
| 2021-04-21 | Janet S. Vergis Independent Director Committees: Human Resources and Compensation, Compliance Ms. Vergis joined the Board of Directors in June 2020. She served as a retained executive advisor to various private equity firms from 2013 to 2019. From 2011 to 2012, she served as the Chief Executive Officer of OraPharma, Inc., a specialty pharmaceutical company. From 2004 to 2009, she served as President of Janssen Pharmaceuticals LP, McNeil Pediatrics, Inc. and Ortho-McNeil Neurologics, Inc., subsidiaries of Johnson & Johnson. Ms. Vergis contributed to a number of Johnson & Johnson companies during her career, holding positions of increasing responsibility in research and development, new product development, sales and marketing. Ms. Vergis has served on the board of directors of Church and Dwight Co., Inc. since 2014, Dentsply-Sirona, Inc. since 2019 and SGS SA since March 2021. She previously served on the board of directors of MedDay Pharmaceuticals from 2016 to 2021, Amneal Pharmaceutical from 2015 to 2019, Lumara Health from 2013 to 2014 and OraPharma, Inc. from 2011 to 2012. Ms. Vergis received a Bachelor of Science in Biology and a Masters of Science in Physiology from The Pennsylvania State University. 2020 Director Compensation: Janet S. Vergis Fees Earned or Paid in Cash ($) 86,007 Stock Awards ($) 159,997 Total ($) 246,004 |
| 2022-04-13 | Janet S. Vergis Independent Director Committees: Human Resources and Compensation Compliance Ms. Vergis joined the Board of Directors in 2020. She served as a retained executive advisor to various private equity firms from 2013 to 2019. From 2011 to 2012, she served as the Chief Executive Officer of OraPharma, Inc., a specialty pharmaceutical company. From 2004 to 2009, she served as President of Janssen Pharmaceuticals LP, McNeil Pediatrics, Inc. and Ortho-McNeil Neurologics, Inc., subsidiaries of Johnson Johnson. Ms. Vergis contributed to a number of Johnson Johnson companies during her career, holding positions of increasing responsibility in research and development, new product development, sales and marketing. Ms. Vergis has served on the board of directors of Church and Dwight Co., Inc. since 2014, Dentsply-Sirona, Inc. since 2019 and SGS SA since March 2021. She previously served on the board of directors of MedDay Pharmaceuticals from 2016 to 2021, Amneal Pharmaceutical from 2015 to 2019, as well as Lumara Health from 2013 to 2014 and OraPharma, Inc. from 2011 to 2012. Ms. Vergis received a Bachelor of Science in Biology and a Masters of Science in Physiology from The Pennsylvania State University. |
| 2023-04-19 | Janet S. Vergis joined the Board of Directors in 2020. ... Committees: Compliance (Chair), Human Resources and Compensation. ... 2022 Director Compensation: Fees Earned or Paid in Cash $155,000, Stock Awards $159,997, Total $314,997. |
| 2024-04-16 | Janet S. Vergis Independent Director Committees: Compliance (Chair), Human Resources and Compensation, Corporate Governance and Nominating ... Ms. Vergis joined the Board of Directors in 2020. ... 2023 Director Compensation table shows Janet S. Vergis total compensation as $325,458. |
Data sourced from SEC filings. Last updated: 2025-12-06